EU AI Act Scope May Extend to Internal Research Models
Legal distinctions between market placement and internal service could force AI labs to disclose proprietary research pipelines.
The European Union's AI Act may apply to high-capability AI models used exclusively for internal research, potentially expanding the compliance burden for AI laboratories. This regulatory reach depends on whether internal deployment triggers the Act's stringent safety and transparency mandates.
At the center of the issue is a critical legal distinction within EU product law between "placing on the market" and "putting into service." While the former refers to making a product available for sale or distribution, the latter can encompass the internal deployment of a system within an organization. If internal research models are classified as being "put into service," they would fall under the Act's regulatory umbrella regardless of whether they ever reach a consumer.
The GPAI Framework
The EU AI Act utilizes a tiered system of obligations based on the risk level of the AI system. General Purpose AI (GPAI) models are subject to a baseline of transparency and copyright requirements. However, models identified as posing "systemic risks" face significantly more stringent obligations, including rigorous safety and security assessments.
Impact on Proprietary Research
If internal models are included in this scope, AI labs would be required to disclose detailed information regarding their research pipelines and safety testing for models that remain proprietary. This shift could force companies to reveal sensitive technical data and internal benchmarks, potentially compromising trade secrets and slowing the pace of research and development.
Regulatory Outlook
Industry observers are now watching how regulators interpret the "putting into service" clause for GPAI models. The final determination will decide whether the EU AI Act serves primarily as a consumer protection tool or as a comprehensive oversight mechanism for the entire lifecycle of AI development, including the earliest stages of internal experimentation. This tension highlights a fundamental conflict between the EU's goal of systemic safety and the industry's need for confidential research environments.